The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. (full – 2009) http://www.fasebj.org/content/23/1/183.long
GPR55 ligands promote receptor coupling to multiple signalling pathways. (full – 2010) http://www.ncbi.nlm.nih.gov/pmc/arti...1/?tool=pubmed
A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. (full – 2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931574/
Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. (full – 2011) http://jpet.aspetjournals.org/content/337/1/236.long
Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55. (full – 2011) http://www.ncbi.nlm.nih.gov/pmc/arti...7/?tool=pubmed
L-α-lysophosphatidylinositol meets GPR55: a deadly relationship. (abst – 2011) http://www.ncbi.nlm.nih.gov/pubmed/21367464
The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. (full – 2012) http://diabetes.diabetesjournals.org.../61/2/281.long
Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22027819
The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microgliadependent neuroprotection after excitotoxic lesion. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24038453
(R,R')-4'-Methoxy-1-naphthylfenoterol Targets GPR55-mediated Ligand Internalization and Impairs Cancer Cell Motility. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24355564
GPR55 ligands promote receptor coupling to multiple signalling pathways. (full – 2010) http://www.ncbi.nlm.nih.gov/pmc/arti...1/?tool=pubmed
A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. (full – 2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931574/
Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. (full – 2011) http://jpet.aspetjournals.org/content/337/1/236.long
Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55. (full – 2011) http://www.ncbi.nlm.nih.gov/pmc/arti...7/?tool=pubmed
L-α-lysophosphatidylinositol meets GPR55: a deadly relationship. (abst – 2011) http://www.ncbi.nlm.nih.gov/pubmed/21367464
The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. (full – 2012) http://diabetes.diabetesjournals.org.../61/2/281.long
Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22027819
The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microgliadependent neuroprotection after excitotoxic lesion. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24038453
(R,R')-4'-Methoxy-1-naphthylfenoterol Targets GPR55-mediated Ligand Internalization and Impairs Cancer Cell Motility. (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24355564